Nativita opened an international research and production facility in Beshenkovichi, Vitebsk region.
This advanced high-tech facility was designed and established with the assistance of expert consultants from the European Union and CIS. The high quality of products and safety of personnel and environment are ensured by special isolation technology.
The production capabilities allow full-cycle manufacturing of drugs (tablets, capsules, and liquid forms) in accordance with the European GMP. The pharmaceutical enterprise is primarily focused on developing and producing innovative drugs for the treatment of cancer. The enterprise includes the only production site in Belarus for manufacturing cytostatic medicines in solid dosage forms with the use of isolators from Italian company Nicomac.
Even before opening this production facility, Nativita was registering and selling its drugs in Belarus. Their pre-packing and packaging was performed at Academpharm, a Belarusian company, but in the future they will be released at the pharmaceutical plant in Beshenkovichi. The company has 13 registered products. In 2017, this list is expected to expand to 20 medicines.